
---
title: '国家药监局应急附条件批准辉瑞公司新冠病毒治疗药物奈玛特韦片_利托那韦'
categories: 
 - 新媒体
 - cnBeta
 - 最新
headimg: 'https://static.cnbetacdn.com/article/2021/1105/0cef00e5c804467.png'
author: cnBeta
comments: false
date: Sat, 12 Feb 2022 01:52:21 GMT
thumbnail: 'https://static.cnbetacdn.com/article/2021/1105/0cef00e5c804467.png'
---

<div>   
昨日，国家药监局根据《药品管理法》相关规定，按照药品特别审批程序，进行应急审评审批，附条件批准辉瑞公司新冠病毒治疗药物奈玛特韦片/利托那韦片组合包装(即Paxlovid)进口注册。<br>
<p><a href="https://static.cnbetacdn.com/article/2021/1105/0cef00e5c804467.png" target="_blank"><img src="https://static.cnbetacdn.com/article/2021/1105/0cef00e5c804467.png" referrerpolicy="no-referrer"></a><a href="https://static.cnbetacdn.com/thumb/article/2021/1106/094f929143a9a42.jpg" target="_blank"><img src="https://static.cnbetacdn.com/thumb/article/2021/1106/094f929143a9a42.jpg" referrerpolicy="no-referrer"></a></p><p>本品为口服小分子新冠病毒治疗药物，用于治疗成人伴有进展为重症高风险因素的轻至中度新型冠状病毒肺炎(COVID-19)患者，例如伴有高龄、慢性肾脏疾病、糖尿病、心血管疾病、慢性肺病等重症高风险因素的患者。</p><p>患者应在医师指导下严格按说明书用药，使用中应高度关注说明书中列明的与其他药物相互作用信息。</p><div class="article-relation"><p><strong>相关文章:</strong></p><p><a href="https://www.cnbeta.com/articles/tech/1199447.htm" target="_blank">辉瑞称其抗病毒药Paxlovid可明显减少COVID-19的住院和死亡人数</a></p><p><a href="https://www.cnbeta.com/articles/tech/1204339.htm" target="_blank">95国有机会获得辉瑞新冠口服药Paxlovid仿制药</a></p><p><a href="https://www.cnbeta.com/articles/tech/1215783.htm" target="_blank">欧洲药管局建议可紧急使用辉瑞新冠口服药PAXLOVID</a></p><p><a href="https://www.cnbeta.com/articles/science/1221797.htm" target="_blank">先进光子源APS助辉瑞研发出COVID-19抗病毒治疗药物Paxlovid</a></p></div>   
</div>
            